{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.51","value":"-0.30"},{"groupId":"OG001","spread":"0.43","value":"-0.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Blood samples were collected to evaluate the hematology parameter RBC. Change from Baseline was defined as the value of Baseline minus from the End of study visit. Baseline was defined as Day 1.","dispersionType":"Standard Deviation","groups":[{"description":"The eligible participants in this arm received 5 g of SRT501, oral suspension every morning at the same time approximately 15-30 minutes following consumption of breakfast) on all dosing days, for 20 consecutive days in a 21-day cycle for a maximum period of 12 cycles. There was no time between the cycles i.e Day 1 of a cycle was started on the day following Day 21 of the previous cycle. SRT501 was not administered on Day 21 of each cycle.","id":"OG000","title":"SRT501 Monotherapy"},{"description":"The eligible participants in this arm received an intravenous solution of Bortezomib at 1.3 mg/m\\^2 in conjunction with SRT501 (5.0 g/day) daily dosing. Bortezomib was administered prior to breakfast and SRT501 administration, on Day 1, 4, 8 and 11 in every 21 day cycle. It was given as per the local institution's guidelines and standards of care. SRT501 + Bortezomib, is a subset of arm SRT501 monotherapy.","id":"OG001","title":"SRT501 + Bortezomib"}],"paramType":"MEAN","populationDescription":"Safety population. Only those participants available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and End of Study assessments/follow-up approximately 28 days (+/- 7 days) following the last dose of SRT501 or SRT501 and bortezomib (approximately 280 days)","title":"Change From Baseline in Hematology: Red Blood Cell (RBC)","type":"PRIMARY","unitOfMeasure":"10^12 cells per liter"}